With prescription drug prices continuing to strain state budgets, the National Governors Association is planning a meeting later this year to explore strategies for lowering costs, notably for hepatitis C drugs. And payers and drug makers will be invited, according to one state official familiar with the plan.

Details have not been disclosed, but the effort reflects ongoing concern that some medicines remain out of reach for people who rely on cash-strapped state Medicaid programs, according to Dr. Rebekah Gee, the Louisiana Department of Health secretary, who has been involved in the planning.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy